In the past 30 days, estimates for ADC Therapeutics' 2023 loss per share have narrowed from $2.69 to $2.43. During the same period, the loss per share estimates for 2024 have narrowed from $3.07 to $2.73. In the year so far, shares of ADC Therapeutics have declined 27.1%.